[Federal Register Volume 72, Number 26 (Thursday, February 8, 2007)]
[Notices]
[Pages 5975-5976]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-2077]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Co-Exclusive License

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a limited field of use, 
exclusive license in China, and a co-exclusive worldwide (excluding 
China) license to practice the invention embodied in the patent 
application referred to below to Ringpu (Baoding) Biologics and 
Pharmaceuticals Co. LTD., having a place of business in Baoding City, 
Hebel Province, PR China. CDC intends to grant rights to practice this 
invention (in territories other than China) to no more than two other 
co-licensees. The patent rights in these inventions have been assigned 
to the government of the United States of America. The patent 
application to be licensed is:

Provisional Patent Application

    Title: Method of Sequencing Whole Viral Genomes, Related 
Compositions, and Genome Sequences.
    Serial No. 60/727,038.
    Filing date: 10/14/2005.

PCT Patent Application

    Title: Rabies Virus Compositions and Methods.
    Serial No.: N/A.
    Filing Date: 10/13/2006.
    Domestic Status: N/A.
    Issue Date: patent pending.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    The critical feature of this technology is the ERA rabies virus 
whole genome DNA sequence. With the availability of the entire rabies 
genome, a recombinant vaccine can be developed using reverse genetics. 
The vaccines that can be developed using this genome are fundamentally 
different from classic ones that are being produced. The technology is 
being applied to other negative stranded RNA viruses.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for an exclusive license to the 
territory of China filed in response to this notice will be treated as 
objections to the grant of the contemplated exclusive license. Only 
written comments and/or applications for a license which are received 
by CDC within thirty days of this notice will be

[[Page 5976]]

considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement will be required to receive a copy of any pending patent 
application.

    Dated: January 31, 2007.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E7-2077 Filed 2-7-07; 8:45 am]
BILLING CODE 4163-18-P